CoChat

Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence

Adrean, Sean D., Chaili, Siyang, Pirouz, Ash, Grant, Scott · 2021 · Graefe's Archive for Clinical and Experimental Ophthalmology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Purpose To assess vision, injection quantity, initial lesion size, and final anatomic status in patients with nAMD completing the treat-extend-stop (TES) protocol.Methods Patients with nAMD received ≥ 3 monthly anti-VEGF injections followed by 1-2 week injection interval extensions, with intra/subretinal fluid resolution on SD-OCT, to 12 weeks. With quiescent disease, and 2 quarterly injections, patients were monitored alone beginning at 4 weeks extending by 1-2 week intervals until quarterly monitoring.Results Eighty-eight of 143 eyes with nAMD completed the TES protocol without disease recurrence. Sixteen (18.2%) developed sub-foveal geographic atrophy (GA), 25 (28.4%) developed fibrovascular scarring (FV) and 47 (53.4%) developed regressed choroidal neovascularization (rCNV) with 16.9 ± 13.3 average injections between the 3 groups which was not statistically significant. Average treatment time was 30.3 ± 26.1 months and subsequent follow-up was 23.2 ± 19.8 months. Average lesion size for FV was 18.77 ± 10.8mm 2 vs. GA at 12.00 ± 9.99mm 2 vs. regressed CNV at 7.12 ± 6.5mm 2 (p < 0.05). Pre, post, and final vision for GA was 39.6 letters (20/160) vs. 32.7 letters (20/200 + 2, p = 0.4725) vs. 25.0 letters (20/320, p = 0.0865); FV was 22.4 letters (20/400 + 2) vs. 11.6 letters (20/640, p = 0.0351) vs. 11.0 letters (20/640 + 1, p = 0.0226), and rCNV was 56.4 letters (20/80 + 1) vs. 69.5 letters (20/40, p < 0.001) vs. 67.3 letters (20/40-2, p = 0.0016). In the rCNV group, 17/46 eyes gained ≥ 3 lines and 30/46 eyes achieved ≥ 20/40 vision. Non-central GA expanded 0.226 ± 0.126 mm vs. 0.225 ± 0.098 mm during and after treatment completion over 24 months (p = 0.99).Conclusions Central GA or FV portends worse visual outcomes vs. rCNV after cessation of therapy. Anti-VEGF therapy may not affect the rate of GA expansion. Final anatomic character and location are key determinants of final vision.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00417-021-05283-0

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 9

Metadata

Authors
Adrean, S. D., Chaili, S., Pirouz, A., & Grant, S.
Affiliations
Vanderbilt University (US)
Corresponding author
Adrean, Sean D.
Venue
Graefe's Archive for Clinical and Experimental Ophthalmology
Published
2021-07-12
Volume
259
Issue
12
Pages
3665-3673
ISSN
  • 0721-832X (ISSN-L)
  • 1435-702X
OpenAlex
W3182777314
Cited by
8
References
33
Citations by year
2026: 1 · 2025: 2 · 2023: 3 · 2022: 2
FWCI
1.13
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, anti-VEGF therapy, geographic atrophy, recurrence, treatment duration, visual acuity outcomes, lesion size, patient-reported outcomes, quality of life
MeSH terms
Ranibizumab, Humans, Macular Degeneration, Visual Acuity, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. https://app.cochat.ai/papers/10.1007/s00417-021-05283-0
The paper
Adrean, S. D., Chaili, S., Pirouz, A., & Grant, S. (2021). Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-021-05283-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.